Scrutiny of drug and consumer product giant Johnson & Johnson ratcheted up as a congressional chairman demanded the company provide proof of its claim that federal regulators cleared a plan to secretly buy up defective painkillers.
The Justice Department has joined a whistleblower lawsuit that accuses Wyeth Pharmaceuticals of promoting the off-label use of a transplant drug in high-risk black patients, children and others.
Merck KGaA announced that the Australian Therapeutic Goods Administration has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis.
Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired bacterial pneumonia.
GSK and Genmab announced plans to refocus the development program of ofatumumab in autoimmune indications. After review of the program’s full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications .
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, announced key findings from preclinical studies of the company's novel cancer metabolism inhibitor, MPC-9528.
Hybrigenics announced positive outcomes of a clinical tolerance Phase 2a study of daily oral inecalcitol in combination with gold standard Taxotere chemotherapy in hormone-refractory prostate cancer patients.
Micromet, Inc. announced the initiation of a phase 2 trial of the company's lead product candidate blinatumomab in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.
Kimble Chase introduces KimCote plastic coated glassware. KimCote is an ultra-clear coating that is applied to the exterior of laboratory glassware in order to resist breakage and contain leakage.
CB-X Protein Assay is designed to be compatible with all commonly used buffers and reagents and therefore eliminates all concerns about selecting a protein assay that is compatible with a specific protein sample, buffer, or solubilization reagents.
IDT Biologika GmbH, a global integrated contract manufacturer of vaccines and biopharmaceuticals, introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilisation capacity.
Alkermes, Inc. announced that the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL should be approved for the treatment of opioid dependence.
A structural molecule and the cellular pump that regulates its levels influence the severity of pneumonia and could provide new ways of treating the lung infection, which is a leading cause of hospitalization and death.